Effect of duloxetine on pain , function , and quality of life among <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">chemotherapy_2</font> <font color="red">-_2</font> <font color="red">induced_2</font> <font color="red">painful_2</font> <font color="red">peripheral_2</font> <font color="red">neuropathy_2</font> <font color="red">:_2</font> a randomized clinical trial . 
<br>
<br> IMPORTANCE There are no known effective treatments for <font color="red">painful_2</font> <font color="red">chemotherapy_2</font> <font color="red">-_2</font> <font color="red">induced_2</font> <font color="red">peripheral_2</font> <font color="red">neuropathy_2</font> <font color="red">._2</font> 
<br> OBJECTIVE To determine the effect of duloxetine , 60 mg daily , on average pain severity . 
<br> DESIGN , SETTING , AND PATIENTS Randomized , double - blind , placebo - controlled crossover trial at <font color="red">8_1</font> <font color="red">National_1</font> <font color="red">Cancer_1</font> <font color="red">Institute_1</font> <font color="red">(_1</font> <font color="red">NCI)-funded_1</font> <font color="red">cooperative_1</font> <font color="red">research_1</font> <font color="red">networks_1</font> <font color="red">that_1</font> <font color="red">enrolled_1</font> <font color="red">231_2</font> <font color="red">patients_2</font> <font color="red">who_2</font> <font color="red">were_2</font> <font color="red">25_2</font> <font color="red">years_2</font> <font color="red">or_2</font> <font color="red">older_2</font> <font color="red">being_2</font> <font color="red">treated_2</font> <font color="red">at_2</font> <font color="red">community_2</font> <font color="red">and_2</font> <font color="red">academic_2</font> <font color="red">settings_2</font> <font color="red">between_2</font> <font color="red">April_2</font> <font color="red">2008_2</font> <font color="red">and_2</font> <font color="red">March_2</font> <font color="red">2011_2</font> <font color="red">._2</font> Study follow - up was completed July 2012 . Stratified by chemotherapeutic drug and comorbid pain risk , patients were randomized to receive either duloxetine followed by placebo or placebo followed by duloxetine . Eligibility required that <font color="red">patients_1</font> <font color="red">have_1</font> <font color="red">grade_1</font> <font color="red">1_1</font> <font color="red">or_1</font> <font color="red">higher_1</font> <font color="red">sensory_1</font> <font color="red">neuropathy_1</font> <font color="red">according_1</font> <font color="red">to_1</font> <font color="red">the_1</font> <font color="red">NCI_1</font> <font color="red">Common_1</font> <font color="red">Terminology_1</font> <font color="red">Criteria_1</font> <font color="red">for_1</font> <font color="red">Adverse_1</font> <font color="red">Events_1</font> <font color="red">and_1</font> <font color="red">at_1</font> <font color="red">least_1</font> <font color="red">4_1</font> <font color="red">on_1</font> <font color="red">a_1</font> <font color="red">scale_1</font> <font color="red">of_1</font> <font color="red">0_1</font> <font color="red">to_1</font> <font color="red">10_1</font> <font color="red">,_1</font> <font color="red">representing_1</font> <font color="red">average_1</font> <font color="red">chemotherapy_1</font> <font color="red">-_1</font> <font color="red">induced_1</font> <font color="red">pain_1</font> <font color="red">,_1</font> <font color="red">after_1</font> <font color="red">paclitaxel_1</font> <font color="red">,_1</font> <font color="red">other_1</font> <font color="red">taxane_1</font> <font color="red">,_1</font> <font color="red">or_1</font> <font color="red">oxaliplatin_1</font> <font color="red">treatment_1</font> <font color="red">._1</font> 
<br> INTERVENTIONS The initial treatment consisted of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks . 
<br> MAIN OUTCOME MEASURES The primary hypothesis was that duloxetine would be more effective than placebo in decreasing chemotherapy - induced <font color="red">peripheral_1</font> <font color="red">neuropathic_1</font> <font color="red">pain_1</font> <font color="red">._1</font> Pain severity was assessed using the Brief Pain Inventory - Short Form " average pain " item with 0 representing no pain and 10 representing as bad as can be imagined . 
<br> RESULTS Individuals receiving duloxetine as their initial 5-week treatment reported a mean decrease in average pain of 1.06 ( 95% CI , 0.72 - 1.40 ) vs 0.34 ( 95% CI , 0.01 - 0.66 ) among those who received placebo ( P = .003 ; effect size , 0.513 ) . The observed mean difference in the average pain score between duloxetine and placebo was 0.73 ( 95% CI , 0.26 - 1.20 ) . Fifty - nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo reported decreased pain of any amount . 
<br> CONCLUSION AND RELEVANCE Among <font color="red">patients_2</font> <font color="red">with_2</font> <font color="red">painful_2</font> <font color="red">chemotherapy_2</font> <font color="red">-_2</font> <font color="red">induced_2</font> <font color="red">peripheral_2</font> <font color="red">neuropathy_2</font> <font color="red">,_2</font> the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain . 
<br> TRIAL REGISTRATION clinicaltrials.gov Identifier : NCT00489411 .